Laboratory research involving 5-Amino-1MQ has focused on selective NNMT inhibition and its effect on diet-induced obesity in mouse models (Learn more), and the downstream metabolic consequences of changing nicotinamide methylation, alongside related work on other ageing and metabolic compounds such as NAD+. Experimental models have explored adipocyte biology, cellular energy handling, NAD-related pathways and methyl-donor metabolism.
NNMT: an enzyme that spends methyl groups
Nicotinamide N-methyltransferase was first described in 1951, when Giulio Cantoni showed that a soluble enzyme preparation from rat liver could attach a methyl group to nicotinamide, the amide form of vitamin B3. The reaction is simple on paper. NNMT lifts a methyl group from S-adenosylmethionine (SAM) and places it on the ring nitrogen of nicotinamide, leaving 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH) behind.
What makes the enzyme interesting is where those products go. 1-MNA cannot re-enter the NAD+ salvage route; it is oxidised to pyridone metabolites and excreted. Every turnover therefore removes one nicotinamide that could have been rebuilt into NAD+ and burns one SAM that could have methylated DNA, histones or other substrates. Liver carries the most NNMT, with white fat close behind. Benjamin Cravatt’s group at Scripps went further and described NNMT in cancer cells as a “methylation sink”: by locking methyl units into stable 1-MNA, high-NNMT cells ended up with hypomethylated histones and a shifted gene-expression pattern (Ulanovskaya et al.). One enzyme touching both NAD+ supply and methylation capacity is exactly why a selective inhibitor became such a useful probe.
Designing a quinolinium inhibitor from the product
5-Amino-1MQ came out of Stanley Watowich’s laboratory at the University of Texas Medical Branch in Galveston. Rather than screen at random, the team tested families of N-methylated aromatic cations (quinolinium, isoquinolinium, pyridinium, benzimidazolium and benzothiazolium compounds) that look rather like NNMT’s own product, 1-MNA. Across the set, activity spanned more than a thousand-fold, and the quinolinium scaffold stood out with IC50 values around 1 µM. Computer docking placed these inhibitors in the pocket that normally holds nicotinamide, not in the SAM site, and docking scores tracked the measured potencies closely (Neelakantan et al., J Med Chem).
A follow-up paper asked the practical questions. Methylquinolinium analogues carrying a primary amine, the group to which 5-Amino-1MQ belongs, crossed artificial membranes and Caco-2 cell layers well by both passive and active transport, which is notable for a molecule with a permanent positive charge. They also left structurally related SAM-dependent methyltransferases and the NAD+ salvage enzymes untouched, giving researchers an NNMT tool that does not muddy the pathways it is meant to reveal.
From cultured fat cells to diet-induced obese mice
The rodent groundwork was laid in 2014, when Barbara Kahn’s team used antisense knockdown of Nnmt in the fat and liver of mice on a high-fat diet. Those animals resisted diet-induced weight gain, burned more energy, and showed higher SAM and NAD+ in adipose tissue, along with faster polyamine turnover linked to changes in histone methylation (Kraus et al., Nature).
The Galveston group then tested small-molecule inhibition. In cultured adipocytes, their compounds lowered intracellular 1-MNA, raised NAD+ and SAM, and suppressed lipogenesis. In obese mice kept on a high-fat diet, systemic treatment with a potent member of the series reduced body weight, white adipose mass and adipocyte size and lowered plasma total cholesterol, without changing how much the animals ate. A later study paired 5-amino-1-methylquinolinium with a switch to low-fat chow and found the obese mice converged on age-matched lean controls faster than with the diet change alone, then profiled how their gut microbiome compared. All of this is rodent and cell data, which is precisely the stage the compound occupies.
Ageing muscle stem cells and NNMT inhibition
NNMT climbs with age in skeletal muscle, where it has been tied to a flagging NAD+ salvage pathway, altered sirtuin 1 activity and senescent muscle stem cells. To test whether blocking it could change that picture, the Watowich and Fry laboratories injured the tibialis anterior of 24-month-old mice with barium chloride and gave an NNMT inhibitor for one or three weeks. Stem-cell proliferation and fusion rose, regenerating fibres reached nearly twice the cross-sectional area of controls, and peak torque of the injured muscle was about 70% higher. C2C12 myoblasts in culture differentiated more readily, with matching shifts in their NAD+/NADH balance (Neelakantan et al., Biochem Pharmacol).
A 2024 study in Scientific Reports named 5A-1MQ as its inhibitor and treated mice from 22 to 24 months of age, with or without progressive weighted wheel running. Sedentary treated mice showed roughly 40% greater grip strength than sedentary controls, exercise alone about 20%, and the combination around 60%. Intramyocellular lipid fell, and proteome and metabolome analyses pointed to distinct molecular signatures for the drug, the exercise and the pairing (Dimet-Wiley et al.).
